After Novo Holdings set the stage for a $16.5 billion buyout of contract manufacturing giant Catalent earlier this year, its ...
Danaher Corporation is a leading player in the life science industry, with strong financial performance despite many spin-offs. The healthcare industry is facing challenges due to weak funding and ...
Danaher Corporation DHR is well poised for growth courtesy of strength across its end markets, strategic acquisitions and its focus on improving the product line and operational excellence.
Deep-pocketed investors have adopted a bearish approach towards Danaher DHR, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...
LONDON, April 12 (Reuters Breakingviews) - For any ambitious M&A adviser, there’s obvious appeal in pitching clients on a potential takeover of BP (BP.L) , opens new tab. The $110 billion energy ...
Danaher Corp (NYSE: DHR) has logged Q1 FY23 adjusted EPS of $2.36, down from $2.76 a year ago, surpassing the consensus of $2.25. Sales decreased 7% Y/Y to $7.17 billion, beating the consensus of ...
The latest trading session saw Danaher (DHR) ending at $248.77, denoting a +0.12% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of 0.86%.
Danaher DHR has outperformed the market over the past 5 years by 4.4% on an annualized basis producing an average annual return of 16.94%. Currently, Danaher has a market capitalization of $186.08 ...
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments ...